Hemoglobin SC Disease clinical trials
The registry lists 32 studies for Hemoglobin SC Disease across more than 10 countries. 2 are recruiting or about to start. 11 of them are mainly about Hemoglobin SC Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04.
Get an email when these change. Save the Hemoglobin SC Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Ann & Robert H Lurie Children's Hospital of Chicago (4) · Baylor College of Medicine (3) · Novartis Pharmaceuticals (2) · Sangart (2) · St. Jude Children's Research Hospital (2) · Tami D. John (1) · Majmaah University (1) · Natasha Archer (1)
What is being tested here
Drugs under test in Hemoglobin SC Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Buprenorphine | 1 | 0 | 1 |
| Hydroxyurea | 0 | 0 | 4 |
| Crizanlizumab | 0 | 0 | 2 |
| Cyclophosphamide | 0 | 0 | 2 |
| Pyrrolidonecarboxylic Acid | 0 | 0 | 2 |
| Tovinontrine | 0 | 0 | 1 |
| Ancestim | 0 | 0 | 1 |
| Fludarabine | 0 | 0 | 1 |
| Cytarabine | 0 | 0 | 1 |
| Bortezomib | 0 | 0 | 1 |
Drug classes tested here Antimetabolites 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Oct 2027Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease · National Heart, Lung, and Blood Institute (NHLBI)
Who these studies take
Of the 1 Hemoglobin SC Disease studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 32 studies, recruiting or not: 50% stop at 75 or younger and 38% at 65; 66% take children; 0% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 32 of 32. search them.
- Buprenorphine for the Management of Pain in Children With Sickle Cell DiseaseNot yet recruitingNCT07799571Phase 11 country
- Sickle Cell Disease and the Genomic and Gene Therapy Needs of StakeholdersRecruitingNCT044161781 country
- Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell DiseaseActive, not recruitingNCT056754361 country
- Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell DiseaseCompletedNCT00600665Not applicable1 country
- The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.CompletedNCT04691323Not applicable1 country
- An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell DiseaseCompletedNCT04688411Not applicable1 country
- An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease PatientsCompletedNCT04662931Phase 41 country
- Treatment of Sickle Cell Anemia With Stem Cell TransplantTerminatedNCT01350232Not applicable1 country
- A Study of IMR-687 in Healthy Adult VolunteersCompletedNCT02998450Phase 11 country
- ERN-EuroBloodNet Registry on Patients with Rare Red Blood Cell Defects and COVID-19CompletedNCT068317991 country
- Pharmacokinetics of Oral Hydroxyurea SolutionCompletedNCT03763656Phase 1/22 countries
- Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)CompletedNCT03264989Phase 21 country
- Evaluation of a Training Program for Homozygous Sickle Cell Disease PatientsCompletedNCT02571088Not applicable1 country
- Parent Educational Program for Children With Sickle Cell DiseaseCompletedNCT00860782Not applicable1 country
- Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go AppCompletedNCT04675645Not applicable1 country
- Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility StudyCompletedNCT04678037Not applicable1 country
- Effect of Walking on Sand With Dietary Intervention in Overweight Type 2 Diabetes Mellitus Patients.CompletedNCT04364685Not applicable1 country
- Treatment of Hemoglobin SC Disease With HydroxyureaTerminatedNCT02336373Phase 21 country
- Bone Marrow Transplantation, Hemoglobinopathies, SCALLOPTerminatedNCT00578344Not applicable1 country
- Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)TerminatedNCT02640573Phase 21 country
- Role of Ajwa Derived Polyphenols in DyslipidaemiasStatus unknownNCT03805139Not applicable1 country
- A Sickle CEll Disease ComplicatioN TrialStatus unknownNCT02604368Phase 3
- Decision Aid for Therapeutic Options In Sickle Cell DiseaseCompletedNCT02326597Not applicable1 country
- Ketamine Sickle Cell DiseaseWithdrawnNCT03502421Phase 3
- Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle CrisisWithdrawnNCT01925001Phase 29 countries
- Safety Study of MP4CO in Adult Sickle Cell PatientsCompletedNCT01356485Phase 14 countries
- Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With HemoglobinopathiesCompletedNCT00153985Phase 21 country
- Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or ThalassemiaTerminatedNCT00034528Phase 21 country
- Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell DiseaseTerminatedNCT00532883Phase 21 country
- Oral Magnesium Pidolate, Hemoglobin SC Disease, MG PidolateTerminatedNCT00040456Phase 21 country
- Far Infrared Radiation for Sickle Cell Pain ManagementStatus unknownNCT00599482Phase 11 country
- A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling DisordersCompletedNCT00005783Phase 11 country